Patients and Donors Characteristics
| . | BM Group . | PBSC Group . | CD34 Group . |
|---|---|---|---|
| No. of patients | 45 | 45 | 18 |
| Median age in years (range) | |||
| Recipients | 34 (9-55) | 35 (5-56) | 37 (7-56) |
| Donors | 34 (22-53) | 29 (21-52) | 32 (23-53) |
| Recipient sex (F/M) | 18/27 | 23/22 | 5/13 |
| Donor sex (F/M) | 14/30 | 16/29 | 5/13 |
| Female donor, male recipient | 6 | 4 | 4 |
| Diagnoses | |||
| Acute myeloid leukemia | |||
| CR1 | 4 | 4 | 2 |
| CR2 | 4 | 3 | 1 |
| PR | 2 | 3 | 1 |
| Early relapse | 1 | 2 | — |
| Relapse | 6 | 5 | — |
| Acute lymphoid leukemia | |||
| CR1 | 1 | 1 | — |
| CR2-3 | 2 | 2 | 2 |
| PR | 1 | — | — |
| Relapse | 2 | 2 | 1 |
| Chronic myeloid leukemia | |||
| cp1 | 14 | 15 | 4 |
| cp2 | 2 | 1 | — |
| Accelerated phase | 3 | 3 | 2 |
| Blast crisis | 2 | 2 | 1 |
| Myelodysplastic syndrome | — | — | 2 |
| Lymphoma CR1 | — | 1 | — |
| Aspartylglucosaminuria | 1 | 1 | — |
| Aplastic anemia | — | — | 1 |
| Low risk/high risk† | 19/25 | 21/23 | 6/11 |
| Cytomegalovirus serology | |||
| Recipient +/− | 25/20 | 22/23 | 9/7 |
| Donor +/− | 20/25 | 24/21 | 7/9 |
| Median observation time in months (range) | 16 (5-37) | 10 (1-32) | 8 (3-20) |
| . | BM Group . | PBSC Group . | CD34 Group . |
|---|---|---|---|
| No. of patients | 45 | 45 | 18 |
| Median age in years (range) | |||
| Recipients | 34 (9-55) | 35 (5-56) | 37 (7-56) |
| Donors | 34 (22-53) | 29 (21-52) | 32 (23-53) |
| Recipient sex (F/M) | 18/27 | 23/22 | 5/13 |
| Donor sex (F/M) | 14/30 | 16/29 | 5/13 |
| Female donor, male recipient | 6 | 4 | 4 |
| Diagnoses | |||
| Acute myeloid leukemia | |||
| CR1 | 4 | 4 | 2 |
| CR2 | 4 | 3 | 1 |
| PR | 2 | 3 | 1 |
| Early relapse | 1 | 2 | — |
| Relapse | 6 | 5 | — |
| Acute lymphoid leukemia | |||
| CR1 | 1 | 1 | — |
| CR2-3 | 2 | 2 | 2 |
| PR | 1 | — | — |
| Relapse | 2 | 2 | 1 |
| Chronic myeloid leukemia | |||
| cp1 | 14 | 15 | 4 |
| cp2 | 2 | 1 | — |
| Accelerated phase | 3 | 3 | 2 |
| Blast crisis | 2 | 2 | 1 |
| Myelodysplastic syndrome | — | — | 2 |
| Lymphoma CR1 | — | 1 | — |
| Aspartylglucosaminuria | 1 | 1 | — |
| Aplastic anemia | — | — | 1 |
| Low risk/high risk† | 19/25 | 21/23 | 6/11 |
| Cytomegalovirus serology | |||
| Recipient +/− | 25/20 | 22/23 | 9/7 |
| Donor +/− | 20/25 | 24/21 | 7/9 |
| Median observation time in months (range) | 16 (5-37) | 10 (1-32) | 8 (3-20) |